Earnings Volatility Drives NPS Pharmaceuticals and These Stocks in a New Direction

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. Adjusted Earnings Per Share decreased to $-0.13 in the quarter versus EPS of $0.08 in the year-earlier quarter. Revenue Decreased 31.78% to $36.51 million from the year-earlier quarter.

NPS Pharmaceuticals, Inc. reported adjusted EPS loss of $0.13 per share. By that measure, the company missed the mean analyst estimate of $-0.07. It beat the average revenue estimate of $31.62 million.

NPSP 20130811

Nektar Therapeutics (NASDAQ:NKTR) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share decreased to $-0.37 in the quarter versus EPS of $-0.30 in the year-earlier quarter. Revenue Rose 42.99% to $33.86 million from the year-earlier quarter.

Nektar Therapeutics reported adjusted EPS loss of $0.37 per share. By that measure, the company beat the mean analyst estimate of $-0.44. It beat the average revenue estimate of $26.22 million.

NKTR 20130811

Geron Corporation (NASDAQ:GERN) had a loss and met Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share decreased to $-0.07 in the quarter versus EPS of $-0.14 in the year-earlier quarter. Revenue Decreased 15.38% to $110,000 from the year-earlier quarter.

Geron Corporation reported adjusted EPS loss of $0.07 per share. By that measure, the company missed the mean analyst estimate of $-0.07. It beat the average revenue estimate of $0.

GERN 20130811

Zogenix, Inc. (NASDAQ:ZGNX) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased to $-0.13 in the quarter versus EPS of $-0.26 in the year-earlier quarter. Revenue Rose 10.83% to $8.9 million from the year-earlier quarter.

Zogenix, Inc. reported adjusted EPS loss of $0.13 per share. By that measure, the company beat the mean analyst estimate of $-0.15. It beat the average revenue estimate of $8.63 million.

ZGNX 20130811

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased to $-0.22 in the quarter versus EPS of $-0.30 in the year-earlier quarter. Revenue Was the same at $200,000 as the year-earlier quarter.

ZIOPHARM Oncology, Inc. reported adjusted EPS loss of $0.22 per share. By that measure, the company beat the mean analyst estimate of $-0.24.

ZIOP 20130811

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.